-
Mashup Score: 0The Multiple Myeloma Daily - 1 year(s) ago
A selection of articles, blog posts, videos and photos recommended by Robert Z. Orlowski
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Investigators in a new study utilized an “add-on” time-limited treatment approach for patients with #CLL with detectable minimal residual disease #MRD who received treatment with ibrutinib monotherapy in the frontline or relapsed/refractory settings: https://t.co/Nt2Rwy4I4a https://t.co/JQ6JsyeQYN
-
-
Mashup Score: 1
According to initial data presented at the 2023 Gastrointestinal Cancers Symposium, the novel, personalized, tumor-informed brPROPHET technology was more sensitive in detecting molecular residual disease vs other assays.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Detecting ctDNA & identifying #MRD in patients with colorectal cancer after surgery was assessed with greater sensitivity using #brPROPHET vs alternatives, according to findings presented at the 2023 Gastrointestinal Cancers Symposium. #GI23 #gicsm https://t.co/gnGziMWzIc
-
-
Mashup Score: 2
According to initial data presented at the 2023 Gastrointestinal Cancers Symposium, the novel, personalized, tumor-informed brPROPHET technology was more sensitive in detecting molecular residual disease vs other assays.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Detecting #ctDNA and identifying #MRD in patients with colorectal cancer after surgery was assessed with greater sensitivity using brPROPHET. #crcsm #GI23 https://t.co/B6uC0v0DbO
-
-
Mashup Score: 0
Gayathri Ravi, MD, discusses the role of minimal residual disease testing in patients with newly diagnosed multiple myeloma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Investigators sought to evaluate the reproducibility of quadruplet induction/consolidation therapy, #ASCT, and #MRD-informed treatment in the real-world setting. #hematology #ASH22 https://t.co/7M6UEKUzBu
-
-
Mashup Score: 0Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Investigators in a new study utilized an “add-on” time-limited treatment approach for patients with #CLL with detectable minimal residual disease #MRD who received treatment with ibrutinib monotherapy in the frontline or relapsed/refractory settings: https://t.co/Nt2Rwy4I4a https://t.co/NTd3MmwaOT
-
-
Mashup Score: 0
Months after the FDA granted accelerated approval to dostarlimab for this rectal cancer indication, phase 2 data have confirmed its efficacy and safety.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Maged Khalil, MD, discussed historic issues with treating #MRD, locally advanced rectal cancer, and the subgroups in the most need for new treatment options. #crcsm | @MSKCancerCenter https://t.co/xCjvdQp0hK
-
-
Mashup Score: 3Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia - 1 year(s) ago
Key Points. Targeted sequencing of dysplastic cells and blasts at diagnosis identifies evolutionary patterns from dysplasia to the onset of AML.Patients with AM
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Looking forward to reading this in detail.Big #hemepath #leusm and #MRD implications Congrats to the authors. Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia @BloodAdvances https://t.co/fWZDeH6CGB
-
-
Mashup Score: 6Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers - 1 year(s) ago
PURPOSE Circulating tumor DNA (ctDNA) analyses allow for postoperative risk stratification in patients with curatively treated colon and breast cancers. Use of ctDNA in esophagogastric cancers (EGC) is less characterized and could identify high-risk patients who have been treated with curative intent. METHODS In this retrospective analysis of real-world data, ctDNA levels were analyzed in the…
Source: JCO Precision OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
👇🏾🆕 @JCOPO_ASCO Delighted to be a part of this important project - one of the largest datasets providing in-depth insights & analyses into #ctDNA🩸🧬 in stomach & esophageal cancers. #STCSM #ESOCSM ➡️Sets the foundation for #MRD-driven📚. @OncoAlert 📌https://t.co/LIYFNqNaF1 https://t.co/I42fOc9awW https://t.co/Izr8CCeRZA
-
-
Mashup Score: 364th ASH Annual Meeting and Exposition: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Targeted Doublet Combinations - 1 year(s) ago
-Author name in bold denotes the presenting author -Asterisk * with author name denotes a Non-ASH member denotes an abstract that is clinically relevant. denotes that this is a recommended PHD Trainee Session. denotes that this is a ticketed session. 642.O1.6 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Targeted Doublet…
Source: ash.confex.comCategories: Hematologists1, Latest HeadlinesTweet-
A whole session on #MRD in #CLL #lymsm and still feels this is not ready for primetime yet! #ASH22 https://t.co/LDGJgpmVus
-
The latest The Multiple Myeloma Daily! https://t.co/I9tZ3vrZ4T Thanks to @MyelomaEurope @HealthTreeMM @MyelomaUK #smolderingmyeloma #mrd